MedTrace Logo

Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project

NCT02945241 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 399

Last updated 2023-10-10

No results posted yet for this study

Summary

Determine if a cystatin C-inclusive vancomycin dosing algorithm improved target trough achievement compared to creatinine clearance-guided vancomycin therapy in critically ill patients.

Conditions

  • Methicillin-resistant Staphylococcus Aureus
  • Sepsis
  • Critical Illness

Interventions

DRUG

Vancomycin

Intravenous

OTHER

Cystatin C dosing algorithm

Expressed in milliliters per minute

OTHER

Creatine clearance dosing algorithm

Vancomycin dosing algorithm based on creatinine clearance, expressed in milliliters per minute

Sponsors & Collaborators

Principal Investigators

  • Erin Frazee, PharmD, RPh · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-06-30
Completion
2016-03-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02945241 on ClinicalTrials.gov